D.E. Shaw & Co
NKGN

D.E. Shaw & Co’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

D.E. Shaw & Co’s Portfolio NKGN Stock Details NKGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-252,656
Closed -$2.56M – 4648
2023
Q1 		$2.56M Hold
252,656
– – ﹤0.01% 2498
2022
Q4 		$2.51M Hold
252,656
– – ﹤0.01% 2741
2022
Q3 		$2.46M Hold
252,656
– – ﹤0.01% 2808
2022
Q2 		$2.45M Hold
252,656
– – ﹤0.01% 2894
2022
Q1 		$2.45M Hold
252,656
– – ﹤0.01% 3113
2021
Q4 		$2.45M Hold
252,656
– – ﹤0.01% 3170
2021
Q3 		$2.45M Buy
+252,656
New +$2.46M ﹤0.01% 2845

Other funds holding NKGN

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
SIM
Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return
SFM
Spartan Fund Management Toronto, Ontario, Canada $30M AUM 11.98% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return

D.E. Shaw & Co's NKGN Position: Q2 2023 in Review

D.E. Shaw & Co sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q2 2023, closing a stake of 252,656 shares — an estimated $2.56M sold.

D.E. Shaw & Co first reported a position in NKGN in Q3 2021 and held it in 7 quarters. The position peaked at $2.56M in Q1 2023. 25 funds tracked by Wall St. Rank hold NKGN as of Q2 2023.

  • D.E. Shaw & Co reported no remaining NKGen Biotech, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • D.E. Shaw & Co sold 252,656 NKGen Biotech, Inc. Common Stock shares in Q2 2023, an estimated $2.56M.
  • D.E. Shaw & Co first reported a position in NKGen Biotech, Inc. Common Stock in Q3 2021 and held it in 7 quarters.
  • D.E. Shaw & Co's NKGen Biotech, Inc. Common Stock position peaked at $2.56M in Q1 2023.
  • 25 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q2 2023.

Based on D.E. Shaw & Co's 13F filing for Q2 2023, filed 14 Aug 2023.